The Motley Fool··Eric VolkmanAgios Pharmaceuticals Surges 13% on Beat Earnings, Expanding Mitapivat Market
Agios Pharmaceuticals surged 13% on strong Q1 earnings, with mitapivat revenue jumping 138% to $20.7M. Company plans supplemental FDA application for sickle cell disease expansion.
AGIOFDA approvalsickle cell disease